DIGITAL EDITION

ARCHIVES

CURRENT ISSUE

Exploring Advancements in the Treatment Landscape for Patients with Parkinson’s Disease
Dr. Robert Hauser, from the University of South Florida, provides an overview of Vyalev (foscarbidopa/foslevodopa), highlighting medication administration and mechanism of action, as well as phase 3 trial findings.
Molecular and Cellular Mechanisms Underlying Neurological and Neuropsychological Manifestations of COVID-19

Innov Clin Neurosci. 2025;22(10–12):14–23. by Samaneh Ghorbani Shirkouhi, MSc; Seyed Sepehr Khatami, MD; Zohair Niroomand, MD; Saeed Sadigh-Eteghad, PhD; Shahrokh Yousefzadeh-Chabok, MD; and Sasan Andalib, PhD Ms. Ghorbani Shirkouhi is

Genetic Disorders That Confer Risk for the Development of Psychosis and White Matter Hyperintensities on T2-weighted Imaging: A Practical Guide for Psychiatrists

Innov Clin Neurosci. 2025;22(10–12):24–32. by Mark A. Colijn, MD, MSc, FRCPC, UCNS Dr. Colijn is with the Department of Psychiatry, Mathison Centre for Mental Health Research and Education, and Hotchkiss

Validation of a Pediatric Cognitive Assessment Tool to Advance Knowledge on Children’s Cognitive Development, Health Risk Factors, and Health-promoting Interventions in Sub-Saharan Regions

Innov Clin Neurosci. 2025;22(10–12):33–51. by Franco Di Cesare, MD; Cristiana Di Carlo, MPhil; and Leonardo Di Cesare, MD All authors are with Leoben Research Aurora in San Vincenzo Valle Roveto

Neurocognitive Disorders: Systematic Review of Approved (2008–2024) and Pipeline Phase III Medications

Innov Clin Neurosci. 2025;22(10–12):57–71. by Jayant Totlani, DO; Muhammad Arsalan Bashir, MBBS; Laurel Tay, BA; Ashley Ngor, BS; Alexander J. Steiner, PsyD; Drew Hirsch, BS; Lorena Contreras, MA; Sabrina Renteria,